CO6290772A2 - Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos - Google Patents

Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos

Info

Publication number
CO6290772A2
CO6290772A2 CO10107938A CO10107938A CO6290772A2 CO 6290772 A2 CO6290772 A2 CO 6290772A2 CO 10107938 A CO10107938 A CO 10107938A CO 10107938 A CO10107938 A CO 10107938A CO 6290772 A2 CO6290772 A2 CO 6290772A2
Authority
CO
Colombia
Prior art keywords
angiopoietina
same
antibodies directed
antibodies
angiopoietin
Prior art date
Application number
CO10107938A
Other languages
English (en)
Inventor
Thomas Boone
Jonathan D Oliner
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40625974&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290772(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO6290772A2 publication Critical patent/CO6290772A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen agentes de enlace específicos, tales como anticuerpos completamente humanos, que se enlazan a angiopoietina 1 y/o angiopoietina 2. También se describen fragmentos de cadena pesada, fragmentos de cadena ligera, y CDRs de los anticuerpos, así como métodos de elaboración y uso de los anticuerpos.
CO10107938A 2008-02-20 2010-09-01 Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos CO6290772A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6663208P 2008-02-20 2008-02-20
US6194308P 2008-06-16 2008-06-16
US13936108P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
CO6290772A2 true CO6290772A2 (es) 2011-06-20

Family

ID=40625974

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10107938A CO6290772A2 (es) 2008-02-20 2010-09-01 Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos

Country Status (32)

Country Link
US (5) US8030025B2 (es)
EP (2) EP2252632B1 (es)
JP (1) JP5739163B2 (es)
KR (1) KR101600639B1 (es)
CN (1) CN102046657B (es)
AR (1) AR070453A1 (es)
AU (1) AU2009215804B2 (es)
BR (1) BRPI0907530B1 (es)
CA (2) CA2715324C (es)
CL (1) CL2009000379A1 (es)
CO (1) CO6290772A2 (es)
CR (1) CR11658A (es)
CY (1) CY1115321T1 (es)
DK (1) DK2252632T3 (es)
EA (1) EA022308B1 (es)
ES (2) ES2453342T3 (es)
HK (1) HK1149023A1 (es)
HR (1) HRP20140341T1 (es)
IL (1) IL207445A (es)
JO (1) JO2913B1 (es)
MA (1) MA32190B1 (es)
MX (1) MX2010009185A (es)
MY (1) MY156458A (es)
NZ (2) NZ587230A (es)
PE (1) PE20091571A1 (es)
PL (1) PL2252632T3 (es)
PT (1) PT2252632E (es)
RS (1) RS53262B (es)
SI (1) SI2252632T1 (es)
TW (1) TWI433683B (es)
WO (1) WO2009105269A1 (es)
ZA (1) ZA201006173B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
DE102009053584A1 (de) * 2009-11-17 2011-05-19 Airbus Operations Gmbh Trägersystem zum Aufnehmen von Behältern in einem Fahrzeug und Verwendung eines Trägersystems in einem Flugzeug
AU2011248088B2 (en) * 2010-05-04 2015-06-25 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9512220B2 (en) * 2011-04-05 2016-12-06 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR102225422B1 (ko) * 2011-09-30 2021-03-08 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
US20130330745A1 (en) * 2011-12-20 2013-12-12 Abbott Japan Co. Ltd. Methods of prognosis and diagnosis in sepsis
AU2013230750B2 (en) * 2012-03-08 2018-02-01 Medimmune, Llc Methods of treatment with Angiopoietin-2 antibodies
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2014152122A2 (en) 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
AU2014360273A1 (en) 2013-12-06 2016-06-02 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
AU2015229009B2 (en) 2014-03-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US10035823B2 (en) * 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
US20170233467A1 (en) * 2014-10-17 2017-08-17 Amgen Inc. Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
MX2017005642A (es) * 2014-11-10 2017-07-24 Hoffmann La Roche Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
WO2016176427A1 (en) 2015-04-30 2016-11-03 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
JP2021532170A (ja) 2018-06-29 2021-11-25 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 三重特異性アンタゴニスト
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
MX2021012869A (es) * 2019-08-14 2021-12-10 Pharmabcine Inc Anticuerpo anti-tie2 y uso del mismo.
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
JP2023548866A (ja) 2020-10-29 2023-11-21 インダストリアル ポリマーズ アンド ケミカルズ， インコーポレイテッド 病原体監視及び不活性化のエアフィルター
EP4328242A1 (en) * 2021-04-23 2024-02-28 Neortesbio Inc. Antibody specifically binding to angiopoietin-2, or fragment thereof
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN115947818A (zh) * 2022-10-25 2023-04-11 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5981726A (en) 1990-10-12 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US5889157A (en) 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5880268A (en) 1992-01-27 1999-03-09 Icos Corporation Modulators of the interaction between ICAM-R and αd /CD18
US5837822A (en) 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
WO1994000469A1 (en) 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
JPH06153984A (ja) 1992-11-27 1994-06-03 Morinaga & Co Ltd 抗体および抗体ｃＤＮＡ
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
CA2203236A1 (en) 1994-10-28 1996-05-09 Ira Pastan Tumor-specific antibody fragments, fusion proteins, and uses thereof
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997033617A1 (en) 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2264968A1 (en) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
US5977319A (en) 1996-10-21 1999-11-02 Cambridge Antibody Technology Limited Specific binding members for estradiol; materials and methods
AU5154098A (en) 1996-10-31 1998-05-22 Duke University Soluble tie2 receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO1998039027A2 (en) 1997-03-05 1998-09-11 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1071458A4 (en) 1998-03-13 2005-02-16 Dana Farber Cancer Inst Inc HUMANIZED ANTIBODIES AND ITS USES
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
CA2345903C (en) 1998-10-16 2006-09-26 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Molecular pathogenicide mediated plant disease resistance
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2317808A1 (en) 1998-10-30 2000-05-11 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2375033A1 (en) 1999-05-27 2000-12-07 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
JP4587626B2 (ja) 1999-06-07 2010-11-24 イミュネックス・コーポレーション Ｔｅｋアンタゴニスト
EP1208195A2 (en) 1999-06-15 2002-05-29 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001027279A1 (en) 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20020048763A1 (en) 2000-02-04 2002-04-25 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis
EP1130030A1 (en) 2000-03-02 2001-09-05 Roche Diagnostics Corporation Human erythroid differentiation related factor
JP4019615B2 (ja) * 2000-03-10 2007-12-12 富士ゼロックス株式会社 光磁気素子、光磁気ヘッドおよび磁気ディスク装置
WO2001075110A2 (en) 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2004297218B2 (en) 2000-09-07 2012-03-01 Amgen, Inc. Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
US20030166160A1 (en) 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
IL155204A0 (en) 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
CA2429343A1 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
DE10059930A1 (de) 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1355948B1 (en) 2001-01-12 2009-03-11 Molecules of Man AB Materials and methods for treatment of hepatitis c
EP1349935A2 (en) 2001-01-12 2003-10-08 Incyte Genomics, Inc. Molecules for disease detection and treatment
AU2002253889A1 (en) 2001-02-02 2002-10-03 Arizeke Pharmaceuticals, Inc. Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules
CA2443862A1 (en) 2001-04-17 2002-10-24 Peizhi Luo Structure-based construction of human antibody library
CN101508734A (zh) 2001-04-27 2009-08-19 协和发酵麒麟株式会社 抗cd40单克隆抗体
US7074901B2 (en) 2001-05-25 2006-07-11 Serono Genetics Institute S.A. Isolated human vCOL16A1 polypeptide and fragments thereof
JP4152315B2 (ja) 2001-06-28 2008-09-17 協和醗酵工業株式会社 線維芽細胞増殖因子−８に対するヒト化抗体および該抗体断片
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
US20050260195A1 (en) 2001-10-04 2005-11-24 Xtl Biopharmaceuticals Ltd. Treatment of hepatitis B virus infection with human monoclonal antibodies
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AR036833A1 (es) 2001-10-18 2004-10-06 Bayer Corp Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
US7226594B2 (en) 2001-11-07 2007-06-05 Agensys, Inc. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003048328A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
SI1461428T1 (sl) 2001-12-03 2012-07-31 Alexion Pharma Inc Postopek za proizvodnjo hibridnih protiteles
AR037756A1 (es) 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
DE60232101D1 (es) 2001-12-28 2009-06-04 Kyowa Hakko Kogyo Kk
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
JP2005514409A (ja) 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
JP4660189B2 (ja) 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
AU2003272547A1 (en) 2002-09-16 2004-04-30 Abgenix, Inc. Method for the treatment of nephritis using anti-pdgf-dd antibodies
EP1565553A4 (en) 2002-10-09 2007-11-07 Integrigen Inc RECOMBINANT CATALYTIC POLYPEPTIDES AND USES THEREOF
US20040151724A1 (en) 2002-10-31 2004-08-05 Julia Coronella-Wood Antibody fab fragments specific for breast cancer
ATE455853T1 (de) 2002-11-22 2010-02-15 Chugai Pharmaceutical Co Ltd Antikörper gegen geschädigtes gewebe
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
WO2004050032A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies against drugs of abuse
CA2508214A1 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
ATE469920T1 (de) 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1638606B1 (en) 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
MXPA06001353A (es) 2003-08-08 2006-05-04 Abgenix Inc Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos.
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1660537A2 (en) 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
EP1508576A1 (en) 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
DE602004032370D1 (de) 2003-10-16 2011-06-01 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
PL1682178T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby terapii nowotworów wykazujących ekspresje antygenu CD40
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
AU2004287722A1 (en) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
KR20060120161A (ko) 2003-11-28 2006-11-24 아스트라제네카 아베 항체
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
TW200605906A (en) 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
RS53269B (en) 2004-05-27 2014-08-29 Crucell Holland B.V. BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
NZ545720A (en) 2004-07-09 2010-01-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
EP1765871A1 (en) 2004-07-14 2007-03-28 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG N-glycosylated antibody
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009158432A2 (en) * 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CL2009000379A1 (es) 2012-02-24
CA2844188A1 (en) 2009-08-27
PL2252632T3 (pl) 2014-06-30
IL207445A (en) 2015-09-24
SI2252632T1 (sl) 2014-03-31
CY1115321T1 (el) 2017-01-04
MA32190B1 (fr) 2011-04-01
WO2009105269A1 (en) 2009-08-27
US20120034237A1 (en) 2012-02-09
US10336820B2 (en) 2019-07-02
US20120258122A1 (en) 2012-10-11
JP5739163B2 (ja) 2015-06-24
AU2009215804A1 (en) 2009-08-27
IL207445A0 (en) 2010-12-30
HRP20140341T1 (hr) 2014-05-09
TWI433683B (zh) 2014-04-11
US8221749B2 (en) 2012-07-17
US20090226447A1 (en) 2009-09-10
AR070453A1 (es) 2010-04-07
EP2252632B1 (en) 2014-01-15
NZ587230A (en) 2012-08-31
US20170081398A1 (en) 2017-03-23
RS53262B (en) 2014-08-29
PT2252632E (pt) 2014-04-07
HK1149023A1 (en) 2011-09-23
ES2660381T3 (es) 2018-03-22
MY156458A (en) 2016-02-26
KR101600639B1 (ko) 2016-03-07
EP2252632A1 (en) 2010-11-24
MX2010009185A (es) 2011-02-23
JO2913B1 (en) 2015-09-15
AU2009215804B2 (en) 2013-04-18
BRPI0907530B1 (pt) 2021-09-28
US20130336992A1 (en) 2013-12-19
ES2453342T3 (es) 2014-04-07
KR20100118143A (ko) 2010-11-04
PE20091571A1 (es) 2009-10-21
US8030025B2 (en) 2011-10-04
BRPI0907530A2 (pt) 2015-07-28
TW200940092A (en) 2009-10-01
EP2679599A1 (en) 2014-01-01
JP2011525104A (ja) 2011-09-15
NZ600112A (en) 2013-08-30
CA2715324A1 (en) 2009-08-27
CA2715324C (en) 2014-05-13
CN102046657B (zh) 2014-04-09
CN102046657A (zh) 2011-05-04
EA022308B1 (ru) 2015-12-30
EA201001335A1 (ru) 2011-08-30
EP2679599B1 (en) 2018-01-03
DK2252632T3 (da) 2014-04-07
CR11658A (es) 2010-10-11
ZA201006173B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
CR20120105A (es) Proteínas terapéuticas de unión a dll4
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
EA201400579A1 (ru) Антитела к il-36r
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
EA201270228A1 (ru) Полноценные человеческие антитела к btla
EA201390993A1 (ru) Антитела к cd38
CO6531481A2 (es) Proteinas de enlace al antigeno il-23 humanas
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
UY33124A (es) Agentes y epítopos enlazados a wise
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
UY33931A (es) Agentes de union biespecificos
TN2010000169A1 (en) Molecules and methods for modulating complement component
EA201401204A1 (ru) Антитела к il-23p19
UY33274A (es) Proteínas de unión a basigina

Legal Events

Date Code Title Description
FC Application refused
FG Application granted